D&P Bioinnovations has developed a platform off-the-shelf absorbable immunomodulatory medical device implant to regenerate damaged tissue/organs: gastro-intestine, blood vessels, nerves, tendons/ligaments, skin, muscle, etc. This platform technology can address the global regenerative medicine market that is to accrue over €200 billion by the late 2020s (>€1T for Deep Tech Applications to attain 1B ++ people). However, D&P’s first therapeutic indication is developing an implantable, bioresorbable medical device to regenerate a damaged esophagus (organ providing food to the stomach) to treat esophageal cancer, Advanced Barrett’s, GERD, and/or pediatric atresia.
